Total Payments
$1,666
2024 Payments
$235.69
Companies
10
Transactions
47
Medicare Patients
1,753
Medicare Billing
$160,681
Payment Breakdown by Category
Food & Beverage$1,666 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,666 | 47 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $390.48 | 4 | $0 (2024) |
| GlaxoSmithKline, LLC. | $375.34 | 5 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $331.18 | 4 | $0 (2024) |
| ABBVIE INC. | $154.35 | 7 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $117.41 | 2 | $0 (2022) |
| Lilly USA, LLC | $91.69 | 3 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $86.54 | 12 | $0 (2018) |
| Sunovion Pharmaceuticals Inc. | $61.45 | 8 | $0 (2017) |
| Actelion Pharmaceuticals US, Inc. | $37.92 | 1 | $0 (2023) |
| Alkermes, Inc. | $20.02 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $235.69 | 3 | AstraZeneca Pharmaceuticals LP ($157.47) |
| 2023 | $149.86 | 2 | GlaxoSmithKline, LLC. ($111.94) |
| 2022 | $737.75 | 13 | AstraZeneca Pharmaceuticals LP ($233.01) |
| 2020 | $20.02 | 1 | Alkermes, Inc. ($20.02) |
| 2019 | $221.70 | 5 | Boehringer Ingelheim Pharmaceuticals, Inc. ($130.01) |
| 2018 | $86.54 | 12 | Takeda Pharmaceuticals U.S.A., Inc. ($86.54) |
| 2017 | $214.82 | 11 | Boehringer Ingelheim Pharmaceuticals, Inc. ($122.95) |
All Payment Transactions
47 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $78.22 | General |
| Category: DIABETES | ||||||
| 02/07/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $116.29 | General |
| Category: Respiratory | ||||||
| 01/19/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug), BREZTRI | Food and Beverage | In-kind items and services | $41.18 | General |
| Category: Respiratory | ||||||
| 12/13/2023 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $37.92 | General |
| Category: Cardiology | ||||||
| 10/02/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $111.94 | General |
| 12/06/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $5.89 | General |
| Category: Cardio-renal | ||||||
| 11/10/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $6.71 | General |
| Category: NEUROSCIENCE | ||||||
| 11/03/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $108.04 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/22/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $114.98 | General |
| Category: NEUROSCIENCE | ||||||
| 09/22/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $10.00 | General |
| Category: NEUROSCIENCE | ||||||
| 09/22/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $2.50 | General |
| Category: NEUROSCIENCE | ||||||
| 08/26/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $111.52 | General |
| Category: Cardio-renal | ||||||
| 08/23/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $6.46 | General |
| Category: NEUROSCIENCE | ||||||
| 07/19/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $107.99 | General |
| Category: RESPIRATORY | ||||||
| 06/09/2022 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $124.97 | General |
| Category: Respiratory | ||||||
| 05/26/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $7.48 | General |
| Category: NEUROSCIENCE | ||||||
| 05/03/2022 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $6.22 | General |
| Category: NEUROSCIENCE | ||||||
| 04/12/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: RESPIRATORY | ||||||
| 12/17/2020 | Alkermes, Inc. | Vivitrol (Drug) | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: CNS | ||||||
| 05/16/2019 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: Neuroscience | ||||||
| 04/11/2019 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $63.01 | General |
| 04/11/2019 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $13.86 | General |
| 03/05/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $5.36 | General |
| Category: DIABETES | ||||||
| 02/28/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $124.65 | General |
| Category: DIABETES | ||||||
| 12/03/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $2.53 | General |
| Category: Central Nervous System (CNS) | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 361 | 540 | $74,060 | $36,419 |
| 2022 | 6 | 410 | 598 | $84,050 | $43,079 |
| 2021 | 8 | 436 | 702 | $89,755 | $41,613 |
| 2020 | 9 | 546 | 830 | $100,460 | $39,570 |
Total Patients
1,753
Total Services
2,670
Medicare Billing
$160,681
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 132 | 280 | $49,000 | $20,069 | 41.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 78 | 78 | $11,700 | $9,352 | 79.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 34 | 39 | $8,775 | $4,349 | 49.6% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2023 | 41 | 42 | $1,680 | $1,397 | 83.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 40 | 42 | $840.00 | $823.20 | 98.0% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 36 | 59 | $2,065 | $428.50 | 20.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 140 | 310 | $54,250 | $22,198 | 40.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 103 | 103 | $15,450 | $12,916 | 83.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 40 | 44 | $9,900 | $5,235 | 52.9% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2022 | 49 | 50 | $2,000 | $1,541 | 77.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 48 | 49 | $980.00 | $942.80 | 96.2% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2022 | 30 | 42 | $1,470 | $244.88 | 16.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 175 | 374 | $65,450 | $27,489 | 42.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 34 | 40 | $9,000 | $5,034 | 55.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 38 | 38 | $5,700 | $4,829 | 84.7% |
| 90674 | Vaccine for influenza derived from cell cultures for administration into muscle, 0.5 ml dosage, quadrivalent, , preservative and antibiotic free | Office | 2021 | 57 | 57 | $2,280 | $1,705 | 74.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 57 | 57 | $1,140 | $896.71 | 78.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 11 | 11 | $2,200 | $874.33 | 39.7% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2021 | 52 | 86 | $3,010 | $503.61 | 16.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 12 | 39 | $975.00 | $280.28 | 28.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 199 | 423 | $73,000 | $23,927 | 32.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 57 | 57 | $8,550 | $6,366 | 74.5% |
| 90674 | Vaccine for influenza for administration into muscle, 0.5 ml dosage | Office | 2020 | 92 | 94 | $3,760 | $2,712 | 72.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 23 | 24 | $5,200 | $2,311 | 44.4% |
| 99495 | Transitional care management services, moderately complexity, requiring face-to-face visits within 14 days of discharge | Office | 2020 | 14 | 14 | $2,800 | $1,734 | 61.9% |
About Dr. James Russell, MD
Dr. James Russell, MD is a Family Medicine healthcare provider based in Sapulpa, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508950379.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Russell, MD has received a total of $1,666 in payments from pharmaceutical and medical device companies, with $235.69 received in 2024. These payments were reported across 47 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($1,666).
As a Medicare-enrolled provider, Russell has provided services to 1,753 Medicare beneficiaries, totaling 2,670 services with total Medicare billing of $160,681. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Sapulpa, OK
- Active Since 10/03/2006
- Last Updated 06/09/2010
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1508950379
Products in Payments
- JARDIANCE (Drug) $331.18
- TRELEGY ELLIPTA (Drug) $232.98
- AIRSUPRA (Drug) $157.47
- QULIPTA (Drug) $124.98
- BREZTRI (Drug) $124.97
- Kerendia (Drug) $117.41
- FARXIGA (Drug) $108.04
- Trintellix (Drug) $76.78
- LATUDA (Drug) $56.93
- UPTRAVI (Drug) $37.92
- UBRELVY (Drug) $26.87
- Vivitrol (Drug) $20.02
- EMGALITY (Drug) $14.82
- Dexilant (Drug) $9.76
- UTIBRON (Drug) $4.52
- VRAYLAR (Drug) $2.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Sapulpa
Dr. Kathryn Zackery, D.o, D.O
Family Medicine — Payments: $1,780
Family Medicine $1,780
Ms. Kelly Shuler, D.o, D.O
Family Medicine — Payments: $1,126
Family Medicine $1,126
Soledad Wang, D.o, D.O
Family Medicine — Payments: $574.47
Family Medicine $574.47
Brandi Shell, Aprn, Fnp-C, APRN, FNP-C
Family Medicine — Payments: $440.16
Family Medicine $440.16
Tony Ho, M.d, M.D
Family Medicine — Payments: $303.56
Family Medicine $303.56
Ryan Wenzel, Md, MD
Family Medicine — Payments: $264.73
Family Medicine $264.73